{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:02:34Z","timestamp":1779318154459,"version":"3.51.4"},"reference-count":32,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14267","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:01:21Z","timestamp":1706702481000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical implications and predictive value of the creatinine\u2011cystatin C ratio in patients with multiple myeloma and renal impairment"],"prefix":"10.3892","volume":"27","author":[{"given":"Yixuan","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, Shandong 250021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"key20240216093956_b1-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"key20240216093956_b2-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"key20240216093956_b3-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"key20240216093956_b4-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"key20240216093956_b5-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"key20240216093956_b6-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20240216093956_b7-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"key20240216093956_b8-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key20240216093956_b9-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.beha.2005.01.012","article-title":"Prognostic features of multiple myeloma","volume":"18","author":"San Miguel","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20240216093956_b10-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40620-018-0492-4","article-title":"Myeloma light chain cast nephropathy, a review","volume":"32","author":"Sathick","year":"2019","journal-title":"J Nephrol"},{"key":"key20240216093956_b11-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3324\/haematol.11463","article-title":"Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma","volume":"92","author":"Ludwig","year":"2007","journal-title":"Haematologica"},{"key":"key20240216093956_b12-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/16.5.1042","article-title":"Screening for renal disease using serum creatinine: Who are we missing?","volume":"16","author":"Duncan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"key20240216093956_b13-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.02870707","article-title":"Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C","volume":"3","author":"Baxmann","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20240216093956_b14-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.semnuclmed.2007.09.003","article-title":"Monitoring renal function and limitations of renal function tests","volume":"38","author":"Prigent","year":"2008","journal-title":"Semin Nucl Med"},{"key":"key20240216093956_b15-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"key20240216093956_b16-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"e0148495","DOI":"10.1371\/journal.pone.0148495","article-title":"A new equation to estimate muscle mass from creatinine and cystatin C","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"key20240216093956_b17-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00280-018-3762-x","article-title":"The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: A systematic review and meta-analysis","volume":"83","author":"He","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240216093956_b18-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/CCM.0000000000002013","article-title":"Evaluating muscle mass by using markers of kidney function: Development of the sarcopenia index","volume":"45","author":"Kashani","year":"2017","journal-title":"Crit Care Med"},{"key":"key20240216093956_b19-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41598-020-58304-z","article-title":"Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients","volume":"10","author":"Tang","year":"2020","journal-title":"Sci Rep"},{"key":"key20240216093956_b20-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12877-022-02925-8","article-title":"Serum creatinine\/cystatin C ratio as a screening tool for sarcopenia and prognostic indicator for patients with esophageal cancer","volume":"22","author":"Zheng","year":"2022","journal-title":"BMC Geriatr"},{"key":"key20240216093956_b21-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.ajkd.2011.10.001","article-title":"What is the goal with endogenous filtration markers-estimation of GFR or prediction of kidney outcomes?","volume":"58","author":"Rule","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"key20240216093956_b22-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13539-012-0079-1","article-title":"Serum creatinine as a marker of muscle mass in chronic kidney disease: Results of a cross-sectional study and review of literature","volume":"4","author":"Patel","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20240216093956_b23-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"e0193384","DOI":"10.1371\/journal.pone.0193384","article-title":"Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction","volume":"13","author":"Bukabau","year":"2018","journal-title":"PLoS One"},{"key":"key20240216093956_b24-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2006.07.004","article-title":"Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma","volume":"248","author":"Mulaomerovi\u0107","year":"2007","journal-title":"Cancer Lett"},{"key":"key20240216093956_b25-ol-27-3-14267","first-page":"505","article-title":"Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis","volume":"6","author":"Kos","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20240216093956_b26-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/ijlh.13695","article-title":"The role of cystatin C in multiple myeloma","volume":"44","author":"Zhang","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"key20240216093956_b27-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12185-012-1049-2","article-title":"Prognostic significance of serum cystatin C in multiple myeloma","volume":"95","author":"N\u00fcckel","year":"2012","journal-title":"Int J Hematol"},{"key":"key20240216093956_b28-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.2008.000638","article-title":"Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration","volume":"94","author":"Terpos","year":"2009","journal-title":"Haematologica"},{"key":"key20240216093956_b29-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jcsm.13006","article-title":"Creatinine-cystatin C ratio and mortality in cancer patients: A retrospective cohort study","volume":"13","author":"Jung","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20240216093956_b30-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00408-022-00568-5","article-title":"Serum creatinine\/cystatin C ratio as a predictor of in-hospital mortality in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease","volume":"200","author":"Chen","year":"2022","journal-title":"Lung"},{"key":"key20240216093956_b31-ol-27-3-14267","doi-asserted-by":"publisher","first-page":"1155520","DOI":"10.3389\/fonc.2023.1155520","article-title":"Serum creatinine\/cystatin C ratio as a prognostic indicator for patients with colorectal cancer","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"key":"key20240216093956_b32-ol-27-3-14267","first-page":"5583","article-title":"Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden","volume":"16","author":"Kwon","year":"2018","journal-title":"Oncol Lett"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T07:40:02Z","timestamp":1708069202000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,31]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14267","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"article-number":"134"}}